In some ways that is good and in others not so meaning we are a long ways from any deal which we need badly. We only have half staff and we must pay the lease on the building. I am surprised that our share3price moved upwards and feel it can't maintain or grow without another big deal. Look no doubt there trust is going to be a big issue moving forward. Our money will be made as the result of a revolutionary drug delivery system coupled with this amazing digital designing that can handle 3 separate types actions. If are not successful enough with what we presently have I don't see any new collaborations and that is what we need to shift gears and hire back our people and pack our institutional buyers and investment funds. I know we can't change what has happen but we need one such as Chad Mirkin to get involved again.
https://mirkin-group.northwestern.edu/people/chad-mirkin/
https://mirkin-group.northwestern.edu/people/chad-mirkin/
Recent XCUR News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:15:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:15:02 PM
- Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions • GlobeNewswire Inc. • 04/02/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 08:40:30 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 08:42:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:32:21 PM
- Exicure, Inc. Reports Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/25/2026 08:18:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:25:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 09:25:41 PM
- Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant • GlobeNewswire Inc. • 02/05/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 09:29:08 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 01/21/2026 06:21:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 05:46:19 PM
- Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings • GlobeNewswire Inc. • 01/21/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 07:09:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 01:42:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2025 01:51:19 AM
- Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting • GlobeNewswire Inc. • 12/08/2025 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 04:50:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2025 09:52:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 09:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:18:23 PM
